Synplogen, a synthetic biology startup spun out of Kobe University's Graduate School of Science, Technology and Innovation that provides custom DNA synthesis and Gene Therapy Biofoundry™ services, has entered into a non-binding Memorandum of Understanding ('MOU') with Ginkgo Bioworks with the intent to advance global DNA manufacturing and gene therapy platform services within the Japanese market.

Synplogen是一家合成生物学初创公司，由神户大学科学、技术与创新研究生院（Kobe University's Graduate School of Science，Technology and Innovation）衍生而来，提供定制的DNA合成和基因治疗生物基础™服务公司已与银杏生物工程（Ginkgo Bioworks）签订了一份不具约束力的谅解备忘录（MOU），旨在推动日本市场的全球DNA制造和基因治疗平台服务。

Synplogen intends to support and introduce Ginkgo's gene therapy services within the Japanese biotechnology and pharmaceutical ecosystem

Synplogen打算在日本生物技术和制药生态系统中支持和引入银杏的基因治疗服务

KOBE, Japan and BOSTON, Dec. 6, 2023 /PRNewswire/ -- Synplogen Co., a synthetic biology startup spun out of Kobe University's Graduate School of Science, Technology and Innovation that provides custom DNA synthesis and Gene Therapy Biofoundry services, and Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced that they have entered into a non-binding Memorandum of Understanding ('MOU').

日本神户和波士顿，2023年12月6日/PRNewswire/--合成生物学初创公司Synplogen Co.，由神户大学科学、技术和创新研究生院（提供定制DNA合成和基因治疗生物基金会服务）和银杏生物工程（NYSE:DNA）组成，银杏生物工程正在构建细胞编程和生物安全的领先平台，今天宣布，他们签署了一份不具约束力的谅解备忘录（“MOU”）。

Together, Synplogen and Ginkgo intend to accelerate the global development of DNA manufacturing and gene therapy platform services in Japan..

Synplogen和Ginkgo打算共同加速日本DNA制造和基因治疗平台服务的全球发展。。

Continue Reading

继续阅读

Synplogen and Ginkgo Bioworks Announce Plans to Accelerate Global DNA Manufacturing and Gene Therapy Platform Services in Japan

Synplogen和Ginkgo Bioworks宣布计划在日本加速全球DNA制造和基因治疗平台服务

Ginkgo and Synplogen will explore global business collaboration opportunities for DNA manufacturing. Synplogen's OGAB™ DNA synthesis services have the ability to synthesize DNA of various lengths up to 100 kbp. OGAB is also capable of complex DNA synthesis, with features such as a high/low guanine-cytosine content and repeat sequences..

银杏和Synplogen将探索DNA制造的全球商业合作机会。Synplogen的OGAB™DNA合成服务能够合成高达100 kbp的各种长度的DNA。OGAB还能够进行复杂的DNA合成，具有鸟嘌呤胞嘧啶含量高/低和重复序列等特征。。

Furthermore, Ginkgo and Synplogen will work to extend the reach of Ginkgo's gene therapy services in Japan. Synplogen plans to collaborate by offering business development and marketing support to connect Ginkgo's services with Japanese biotechnology and pharmaceutical companies. Ginkgo is prepared to utilize its end-to-end AAV gene therapy development platform, coupled with unique expertise in high-throughput design and synthesis optimization, to catalyze advancements in the Japanese bioeconomy..

此外，Ginkgo和Synplogen将努力扩大日本银杏基因治疗服务的范围。Synplogen计划通过提供业务开发和营销支持进行合作，将银杏的服务与日本生物技术和制药公司联系起来。银杏准备利用其端到端AAV基因治疗开发平台，以及高通量设计和合成优化方面的独特专业知识，促进日本生物经济的进步。。

'Japan has long been a leader in developing innovations for the bioeconomy,' said Jason Kelly, co-founder and CEO of Ginkgo Bioworks. 'We're thrilled to partner with Synplogen as we seek to grow our cell and gene therapy service offerings in Japan as well as support the vibrant and innovative Japanese bioeconomy more broadly.''We are so honored that our DNA synthesis technology has been recognized by Ginkgo Bioworks, which is the global biofoundry leader,' said Kazuhiko Yamamoto, Representative Director and CEO of Synplogen.

银杏生物工厂（Ginkgo Bioworks）联合创始人兼首席执行官杰森·凯利（JasonKelly）说，日本长期以来一直是生物经济创新领域的领导者我们很高兴与Synplogen合作，寻求在日本扩大我们的细胞和基因治疗服务，并更广泛地支持充满活力和创新的日本生物经济。”Synplogen代表董事兼首席执行官山本和彦（Kazuhiko Yamamoto）说，我们很荣幸我们的DNA合成技术得到了全球生物基金会领导者银杏生物工程（Ginkgo Bioworks）的认可。

'Ginkgo's services can play a crucial role in driving growth in Japan's bioeconomy. We look forward to the practical impact of Ginkgo's contributions, aligning well with our commitment to advancing innovative solutions for the Japanese biotech sector.'About Ginkgo Bioworks Ginkgo Bioworks is the leading horizontal platform for cell programming, providing flexible, end-to-end services that solve challenges for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals.

“银杏的服务可以在推动日本生物经济增长方面发挥关键作用。我们期待着银杏的贡献产生实际影响，这与我们推进日本生物技术行业创新解决方案的承诺相吻合。”关于银杏生物工程银杏生物工程是细胞编程的领先水平平台，提供灵活的端到端服务，为不同市场的组织解决挑战，从食品和农业到制药，再到工业和特种化学品。

Ginkgo's biosecurity and public health unit, Concentric by Ginkgo, is building global infrastructure for biosecurity to empower governments, communities, and public health leaders to prevent, detect and respond to a wide variety of biological threats. For more information, visit ginkgobioworks.com and concentricbyginkgo.com, read our blog, or follow us on social media channels such as X (formerly known as Twitter) (@Ginkgo and @ConcentricByGBW), Instagram (@GinkgoBioworks and @ConcentricByGinkgo), Threads (@GinkgoBioworks) or LinkedIn.About SynplogenSynplogen Co., Ltd.

银杏生物安全与公共卫生部门（Ginkgo’s biosecurity and public health unit）由银杏（Ginkgo）牵头，正在建设全球生物安全基础设施，以增强政府、社区和公共卫生领导人预防、检测和应对各种生物威胁的能力。有关更多信息，请访问ginkgobioworks.com和concentricbygingo.com，阅读我们的博客，或通过社交媒体渠道关注我们，如X（以前称为Twitter）（@gingo和@ConcentricByGBW）、Instagram（@ginkgobioworks和@concentricbygingo）、Threads（@ginkgobioworks）或LinkedIn。关于SynplogenSynplogen Co.，Ltd。

is a synthetic biology startup established in February 2017, originating from Kobe University's Graduate School of Science, Technology and Innovation. Using o.

是一家成立于2017年2月的合成生物学初创公司，起源于神户大学科学、技术与创新研究生院。使用o。